Therapy for ocular toxoplasmosis

Alejandra De-La-Torre; Miles Stanford; Andre Curi; Glenn J. Jaffe; Jorge E. Gomez-Marin

doi:10.3109/09273948.2011.608915

Therapy for ocular toxoplasmosis

Título traducido de la contribución: Terapia para la toxoplasmosis ocular

Alejandra De-La-Torre
, Miles Stanford
, Andre Curi
, Glenn J. Jaffe
, Jorge E. Gomez-Marin

Producción científica: Contribución a revista › Reseña científica › revisión exhaustiva

54 Citas (Scopus)

Resumen

Propósito: Revisar la evidencia actual para el tratamiento de la toxoplasmosis ocular (OT). Diseño: revisión narrativa y recomendaciones de expertos. Métodos: el metanálisis y artículos originales seleccionados de la literatura médica se revisaron críticamente. Se analizaron recomendaciones de expertos. Resultados: Numerosos estudios observacionales sugieren un beneficio del tratamiento antimicrobiano a corto plazo para la retinocoroiditis toxoplásmica en pacientes inmunocompetentes, aunque su eficacia no se ha demostrado en ensayos clínicos aleatorizados. Un ensayo clínico aleatorizado reveló que el tratamiento intermitente con trimetoprima / sulfametoxazol podría disminuir la tasa de recurrencia en pacientes de alto riesgo. La inyección intravítrea de clindamicina y dexametasona fue una alternativa aceptable al tratamiento clásico para OT en un ensayo clínico aleatorizado. Conclusiones: las opiniones sobre la terapia difieren y la controversia permanece sobre su tipo, eficacia y duración. La terapia intravítrea puede ser prometedora para OT. Una descripción reciente de la presencia de parasitemia en pacientes con toxoplasmosis ocular activa e inactiva plantea nuevas preguntas que deben ser exploradas

Título traducido de la contribución	Terapia para la toxoplasmosis ocular
Idioma original	Inglés estadounidense
Páginas (desde-hasta)	314-320
Número de páginas	7
Publicación	Ocular Immunology and Inflammation
Volumen	19
N.º	5
DOI	https://doi.org/10.3109/09273948.2011.608915
Estado	Publicada - oct 1 2011
Publicado de forma externa	Sí

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Áreas temáticas de ASJC Scopus

Microbiología (médica)

Acceder al documento

10.3109/09273948.2011.608915

Citar esto

@article{efc3ab94498945f58b801b807a3bebe9,

title = "Therapy for ocular toxoplasmosis",

abstract = "Purpose: To review current evidence for the treatment of ocular toxoplasmosis (OT). Design: Narrative review and expert recommendations. Methods: Meta-analysis and selected original articles from the medical literature were reviewed critically. Expert recommendations were analyzed. Results: Numerous observational studies suggest a benefit of short-term antimicrobial therapy for toxoplasmic retinochoroiditis in immunocompetent patients, although its efficacy has not been proven in randomized clinical trials. A randomized clinical trial revealed that intermittent trimethoprim/sulfamethoxazole treatment could decrease the rate of recurrence in high-risk patients. Intravitreal injection of clindamycin and dexamethasone was an acceptable alternative to the classic treatment for OT in a randomized clinical trial. Conclusions: Opinions about therapy differ and controversy remains about its type, efficacy, and length. Intravitreal therapy may be promising for OT. A recent description of the presence of parasitemia in patients with active and inactive ocular toxoplasmosis raises new questions that need to be explored.",

author = "Alejandra De-La-Torre and Miles Stanford and Andre Curi and Jaffe, \{Glenn J.\} and Gomez-Marin, \{Jorge E.\}",

year = "2011",

month = oct,

day = "1",

doi = "10.3109/09273948.2011.608915",

language = "English (US)",

volume = "19",

pages = "314--320",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Therapy for ocular toxoplasmosis

AU - De-La-Torre, Alejandra

AU - Stanford, Miles

AU - Curi, Andre

AU - Jaffe, Glenn J.

AU - Gomez-Marin, Jorge E.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Purpose: To review current evidence for the treatment of ocular toxoplasmosis (OT). Design: Narrative review and expert recommendations. Methods: Meta-analysis and selected original articles from the medical literature were reviewed critically. Expert recommendations were analyzed. Results: Numerous observational studies suggest a benefit of short-term antimicrobial therapy for toxoplasmic retinochoroiditis in immunocompetent patients, although its efficacy has not been proven in randomized clinical trials. A randomized clinical trial revealed that intermittent trimethoprim/sulfamethoxazole treatment could decrease the rate of recurrence in high-risk patients. Intravitreal injection of clindamycin and dexamethasone was an acceptable alternative to the classic treatment for OT in a randomized clinical trial. Conclusions: Opinions about therapy differ and controversy remains about its type, efficacy, and length. Intravitreal therapy may be promising for OT. A recent description of the presence of parasitemia in patients with active and inactive ocular toxoplasmosis raises new questions that need to be explored.

AB - Purpose: To review current evidence for the treatment of ocular toxoplasmosis (OT). Design: Narrative review and expert recommendations. Methods: Meta-analysis and selected original articles from the medical literature were reviewed critically. Expert recommendations were analyzed. Results: Numerous observational studies suggest a benefit of short-term antimicrobial therapy for toxoplasmic retinochoroiditis in immunocompetent patients, although its efficacy has not been proven in randomized clinical trials. A randomized clinical trial revealed that intermittent trimethoprim/sulfamethoxazole treatment could decrease the rate of recurrence in high-risk patients. Intravitreal injection of clindamycin and dexamethasone was an acceptable alternative to the classic treatment for OT in a randomized clinical trial. Conclusions: Opinions about therapy differ and controversy remains about its type, efficacy, and length. Intravitreal therapy may be promising for OT. A recent description of the presence of parasitemia in patients with active and inactive ocular toxoplasmosis raises new questions that need to be explored.

U2 - 10.3109/09273948.2011.608915

DO - 10.3109/09273948.2011.608915

M3 - Literature review

C2 - 21970662

SN - 0927-3948

VL - 19

SP - 314

EP - 320

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 5

ER -

Therapy for ocular toxoplasmosis

Resumen

ODS de las Naciones Unidas

Áreas temáticas de ASJC Scopus

Acceder al documento

Huella

Citar esto